Company: REVB
Filing Date: 2025-09-09
Form Type: 8-K
Source: 0001810560-25-000006
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-09
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On September 9, 2025, Revelation Biosciences, Inc. (the “ Company”) issued a press release titled “ Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study” announcing positive clinical results from the PRIME phase 1b clinical study in chronic kidney disease patients. Additionally, the Company made a corporate presentation with the top-line data available to the public, the corporate presentation can be found on the Company’s website. A copy of the press release and presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

The information in Item 8.01, in Exhibit 99.1 and Exhibit 99.2 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.